1. Jiang, Minlin, Jia, Keyi, Wang, Lei, He, Yayi, Zhou, Caicun. 2021. Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy. In Acta pharmaceutica Sinica. B, 11, 2983-2994. doi:10.1016/j.apsb.2021.01.003. https://pubmed.ncbi.nlm.nih.gov/34729299/
2. França, Monica Malheiros, Mendonca, Berenice Bilharinho. 2021. Genetics of ovarian insufficiency and defects of folliculogenesis. In Best practice & research. Clinical endocrinology & metabolism, 36, 101594. doi:10.1016/j.beem.2021.101594. https://pubmed.ncbi.nlm.nih.gov/34794894/
3. Leber, R, Wise, T W, Mizuta, R, Meek, K. . The XRCC4 gene product is a target for and interacts with the DNA-dependent protein kinase. In The Journal of biological chemistry, 273, 1794-801. doi:. https://pubmed.ncbi.nlm.nih.gov/9430729/
4. Saito, Shinta, Kurosawa, Aya, Adachi, Noritaka. 2016. Mutations in XRCC4 cause primordial dwarfism without causing immunodeficiency. In Journal of human genetics, 61, 679-85. doi:10.1038/jhg.2016.46. https://pubmed.ncbi.nlm.nih.gov/27169690/
5. Mittal, Rama Devi, Gangwar, Ruchika, Mandal, Raju K, Srivastava, Priyanka, Ahirwar, Dinesh K. 2011. Gene variants of XRCC4 and XRCC3 and their association with risk for urothelial bladder cancer. In Molecular biology reports, 39, 1667-75. doi:10.1007/s11033-011-0906-z. https://pubmed.ncbi.nlm.nih.gov/21617942/
6. Koike, Manabu, Yutoku, Yasutomo, Koike, Aki. 2022. Feline XRCC4 undergoes rapid Ku-dependent recruitment to DNA damage sites. In FEBS open bio, 12, 798-810. doi:10.1002/2211-5463.13363. https://pubmed.ncbi.nlm.nih.gov/35000298/
7. Ozdilli, Kursat, Pehlivan, Mustafa, Serin, Istemi, Tomatir, Ayse Gaye, Pehlivan, Sacide. 2021. DNA Repair Genes and Chronic Myeloid Leukemia: ERCC2 (751), XRCC1 (399), XRCC4-Intron 3, XRCC4 (-1394) Gene Polymorphisms. In Mediterranean journal of hematology and infectious diseases, 13, e2021020. doi:10.4084/MJHID.2021.020. https://pubmed.ncbi.nlm.nih.gov/33747401/
智鼠故事 
